CHICAGO – The postoperative addition of nivolumab (Opdivo) to chemoradiotherapy (CRT) extended disease-free survival (DFS) in ...

Approximately 70% of breast cancers are HR-positive/HER2 negative. While activating ESR1 mutations are rare at the time of ...

Merck and Japan-based Daiichi Sankyo have withdrawn their U.S. application for an experimental lung cancer treatment after it ...

The platform ‘Fertility Unfiltered’ encourages open conversations around fertility, highlighting real stories and practical ...

Merck beats Q1 2025 estimates despite Gardasil sales drop, driven by Vaxneuvance, Winrevair & Welireg. Click here to find out ...

Merck & Co. has posted phase 2 data on zilovertamab vedotin in lymphoma, providing more evidence of the narrow safety and ...

A therapy at the center of their $22 billion alliance failed to extend survival in a type of lung tumor, leading the ...

Drugs that boost the body’s immune system to fight disease are showing promise in treating a variety of cancers in earlier ...

Merck's ( NYSE: MRK) experimental antibody drug conjugate zilovertamab vedotin, in combination with standard of care, ...

In the latest instalment of a long-running dispute, the Court of Appeal has recently upheld the High Court judge's view on ...

Merck KGaA (Merck) is filing for global regulatory approvals of its CSF-1R inhibitor pimicotinib after it met the primary and ...

Vepdegestrant, an investigational estrogen receptor (ER) degrader, known as a proteolysis-targeting chimera (PROTAC ), ...